FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 5th, 2021 • Xencor Inc • Pharmaceutical preparations • California
THIS FIRST AMENDMENT (this “Amendment”) to the Collaboration and License Agreement of February 4, 2019 (the “Agreement”), is made as of March 10, 2021 (the “Amendment Effective Date”), by and between, on the one hand, Xencor, Inc., a Delaware corporation, having its principal place of business at 111 West Lemon Avenue, Monrovia, California, 91016 (“Xencor”), and, on the other hand, Genentech, Inc., a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (“GNE”), and F. Hoffmann-La Roche Ltd, a corporation organized and existing under the laws of Switzerland, having its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”). Xencor and Genentech are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” All capitalized terms not otherwise defined in this Amendment shall have the meanings defined in the Agreement.
